

Optimal selection for *BRCA1* and *BRCA2* mutation testing using a combination of 'easy to apply' probability models

D Bodmer¹, MJL Ligtenberg^{1,2}, AH van der Hout³, S Gloudemans¹, K Ansink¹, JC Oosterwijk³ and N Hoogerbrugge^{*,1}

¹Department of Human Genetics, Radboud University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands; ²Department of Pathology, Radboud University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands; ³Department of Clinical Genetics, University Medical Centre Groningen, Groningen University, PO Box 30.001, 9700 RB Groningen, The Netherlands

To establish an efficient, reliable and easy to apply risk assessment tool to select families with breast and/or ovarian cancer patients for *BRCA* mutation testing, using available probability models. In a retrospective study of 263 families with breast and/or ovarian cancer patients, the utility of the Frank (Myriad), Gilpin (family history assessment tool) and Evans (Manchester) model was analysed, to select 49 *BRCA* mutation-positive families. For various cutoff levels and combinations, the sensitivity and specificity were calculated and compared. The best combinations were subsequently validated in additional sets of families. Comparable sensitivity and specificity were obtained with the Gilpin and Evans models. They appeared to be complementary to the Frank model. To obtain an optimal sensitivity, five 'additional criteria' were introduced that are specific for the selection of small or uninformative families. The optimal selection is made by the combination 'Frank \geq 16% or Evans2 \geq 12 or one of five additional criteria'. The efficiency of the selection of families for mutation testing of *BRCA1* and *BRCA2* can be optimised by using a combination of available easy to apply risk assessment models.

British Journal of Cancer (2006) 95, 757–762. doi:10.1038/sj.bjc.6603306 www.bjcancer.com

Published online 15 August 2006

© 2006 Cancer Research UK

Keywords: breast cancer; ovarian cancer; *BRCA1*; *BRCA2*; mutation; probability model

Identification of families at high risk of hereditary breast and/or ovarian cancer contributes to the prevention and early detection of breast and ovarian malignancies. Therefore, genetic testing is offered to women with an increased risk of hereditary breast or ovarian cancer based on familial clustering of breast and/or ovarian cancer, particularly in case of early onset or if breast cancer occurs in a male. Selection criteria to test for *BRCA* mutations vary. Because *BRCA* testing is laborious and expensive, as well as associated with medical, psychological and social consequences for the patient, careful patient selection is required before testing. To obtain optimal ascertainment, many risk assessment models and prior probability models have been developed and evaluated (de la Hoya *et al*, 2003; Domchek *et al*, 2003). Four such models, the Claus, Gilpin, Frank and Evans model (Claus *et al*, 1998; Gilpin *et al*, 2000; Frank *et al*, 2002; Evans *et al*, 2004) are empirically derived scoring systems, easy to apply in daily practice with the use of a pencil and a paper and easy to understand for both counsellor and patient.

With the Claus tables the probability of developing breast cancer can be determined, but not the likelihood of detecting a *BRCA* mutation (as in prior probability models). These tables are based

on series of unselected women with breast cancer. As this model does not account for breast cancer in more than two family members, the presence of ovarian cancer, male breast cancer or bilateral breast cancer, it underestimates the cancer risk in many families and cannot be used solely as a prediction model in the clinic.

The Frank model, developed by Myriad Genetics, is an empirical model correlating the prevalence of *BRCA* mutations with personal and family history of breast and ovarian cancer and is based on thousands of women tested for *BRCA1* and *BRCA2* in a diagnostic setting. The outline of this scoring system is shown in Table 1.

Both previous models do not account for the presence of bilateral breast cancer, although this is a predictor for the presence of *BRCA* mutations (Ligtenberg *et al*, 1999). Gilpin *et al* (2000) defines a family history assessment tool (FHAT) that does include bilaterality and ovarian cancer as well as other suggested variables that are prevalent in *BRCA* families, like prostate cancer and colon cancer diagnosed before age 50 (Bermejo and Hemminki, 2004; Table 1).

Like Gilpin *et al* (2000), Evans *et al* (2005) developed a simple and quick scoring system (Manchester scoring system). This model was developed using empirical data from families tested for *BRCA1* or *BRCA2* mutations. The scoring mainly depends on the type of cancer and age at diagnosis and is different for the prediction of *BRCA1* and *BRCA2* mutation-positive families (Evans1 and Evans2 scores; Table 1). The 10 point cutoff level identifies a > 10% likelihood to find in particular *BRCA2*, but also *BRCA1* mutations.

*Correspondence: Dr N Hoogerbrugge;

E-mail: N.Hoogerbrugge@antrg.umcn.nl

Received 10 February 2006; revised 13 July 2006; accepted 14 July 2006; published online 15 August 2006

Table 1 Outlines of the Frank, Gilpin and Evans scoring systems for the *BRCA* mutation prediction

Prediction model	Outlines
Frank	<ul style="list-style-type: none"> ● Prevalence of mutations in <i>BRCA1</i> and <i>BRCA2</i> correlated with personal and family history of cancer in thousands of women tested for <i>BRCA1</i> and <i>BRCA2</i> in a diagnostic setting. ● Family history includes at least one first- or second-degree relative and excludes proband <p>Characteristics scored for</p> <ul style="list-style-type: none"> ● Age of onset breast cancer (< or \geq 50 years) ● Ovarian cancer at any age ● Combined breast and ovarian cancer within one patient
Gilpin	<ul style="list-style-type: none"> ● Weighting system in which points are given to certain characteristics of cancers in affected individuals. The points is predictive for the mutation status ● Family history includes all first, second and third degree family members <p>Characteristics scored for</p> <ul style="list-style-type: none"> ● Age of onset breast cancer (20–29; 30–39; 40–49 years) ● Age of onset ovarian cancer (< 40; 40–60; > 60 years) ● Age of onset prostate cancer (< or \geq 50 years) ● Age of onset colon cancer (< or \geq 50 years) ● Bilateral/multifocal breast tumours ● Combined breast and ovarian cancer within one patient ● Male breast cancer
Evans (<i>BRCA1</i> and <i>BRCA2</i> scored separately)	<ul style="list-style-type: none"> ● Separate scoring system for <i>BRCA1</i> and <i>BRCA2</i> mutation prediction ● Weighting system in which points are given to certain characteristics of cancers in affected individuals. The points is predictive for the mutation status ● Family history includes all first, second and third degree family members ● Each breast cancer if bilateral/multifocal is counted separately <p>Characteristics scored for</p> <ul style="list-style-type: none"> ● Age of onset breast cancer (< 30; 30–39; 40–49; 50–59; > 59 years) ● Age of onset ovarian cancer (< or \geq 60 years) ● Age of onset prostate cancer (< or \geq 60 years) (for <i>BRCA2</i> only) ● Pancreatic cancer at any age (for <i>BRCA2</i> only) ● Male breast cancer (for <i>BRCA2</i> only)

Although the number of *BRCA* analyses increased dramatically over the last 10 years, the number of mutation-positive results did not follow this increase. To reduce the number of negative test results, we correlated the outcome of the aforementioned simple, quick and easy to apply prediction models on families with breast and/or ovarian cancer previously screened for *BRCA* mutations with the mutation status. The sensitivity of the selection criteria was subsequently improved by changing cutoff levels, combining models, and by adding five so-called 'additional selection criteria'. This new combination of selection criteria for *BRCA* testing was validated on two other sets of *BRCA* mutation tested families from two different clinics.

PATIENTS AND METHODS

Study population

The cohort studied consists of 263 families with breast and/or ovarian cancer patients that were tested for *BRCA* mutations, after thorough genetic counselling, between 1999 and 2001, at the Radboud University Medical Centre Nijmegen. Information about the family history was reported to a clinical geneticist by the index patient, that is, the affected family member who was considered to have the highest prior probability of carrying a *BRCA* mutation and who was the first to be tested in the family. The pedigrees were anonymised before analysis and cancer diagnoses were verified wherever possible. In the period 1999–2001, the selection of families for DNA testing was mainly based on expert opinion of clinical geneticists, using the Claus tables (selection when breast cancer risk was three times the population risk: \geq 30%). In 2001 the Gilpin and Frank models were added to the Claus tables and genetic testing was offered if one of these scores was \geq 10. In this study, we used the Myriad mutation prevalence tables of

1 August 2002 (Frank model; <http://www.myriadtests.com/provider/mtprev.htm>).

Validation of the thus defined combination of selection criteria and cutoff levels was performed in two additional family sets. One consisted of 197 breast/ovarian cancer families counselled and tested in 2002 at the Radboud University Medical Centre Nijmegen, of which 34 families were tested *BRCA* mutation-positive. The other set consisted of 101 *BRCA* mutation-positive families counselled and tested at the University Medical Centre Groningen.

Mutation detection in *BRCA1* and *BRCA2*

The mutations were identified by analysis of the entire coding sequences and intron/exon boundaries of the genes using a combination of techniques: protein truncation test of *BRCA1* and *BRCA2* exon 11; denaturing gradient gel electrophoresis of the other coding exons including the 5' and 3' regions of the exons 11 (Hout van der *et al*, 1999); and multiplex ligation-dependent probe amplification to detect exon deletions or duplications (Schouten *et al*, 2002; Hogervorst *et al*, 2003). All positive tests were confirmed by direct sequencing. Unclassified variants were not included in this study.

Scoring systems

The Claus, Frank, Gilpin and Evans scores were determined following description in the published papers. The Evans scores were calculated up till third degree family members.

Data analysis

The significance of the difference between the median prediction scores determined with the different models and correlated with

the mutation status of these families was calculated with a Mann–Whitney *U*-test. We evaluated the different prediction scoring systems and different cutoff levels by calculating the sensitivity, specificity and predictive values. Sensitivity of the selection criteria is the proportion of *BRCA* mutation carriers who fulfil the selection criteria (higher than or equal to the cutoff level). Specificity is the proportion of noncarriers who do not fulfil the selection criteria (below the cutoff level). The positive predictive value is the proportion of individuals who fulfil the selection criteria and who carry a *BRCA* mutation. The negative predictive value is the proportion of individuals who do not fulfil the selection criteria and who do not carry a *BRCA* mutation. We calculated the probability of a *BRCA* mutation for each woman. Subsequently, these probabilities were used to construct a receiver operating characteristic (ROC) curve in order to visualise the predictive power of the variables. The area under the ROC curve (C statistic) quantifies this predictive power.

RESULTS

To determine the *BRCA* mutation prediction capability of the Claus, Frank, Gilpin, Evans1 and Evans2 models, the prediction scores were determined for 263 families with breast and/or ovarian cancer patients and compared to the mutation status of these families. For both the *BRCA*-positive and -negative families, the median prediction scores for the five models were calculated. For the Claus model, no significant difference in this score was observed between *BRCA*-positive and -negative families ($P=0.168$). The Frank, Gilpin, Evans1 and Evans2 model showed a significant difference in the prediction scores ($P<0.0001$) and were studied in more detail.

The prediction scores were also determined for *BRCA1* and *BRCA2* mutation-positive families separately (Figure 1). In all models, the prediction score for the *BRCA1* families was significantly better than for the *BRCA2* families (P -value varied from 0.008 for the Gilpin and Evans1 models to 0.047 for the Frank model). For the Gilpin model, the difference in the prediction scores between *BRCA2* families and noncarriers was not significant ($P=0.113$). The Evans2 gave the best difference between *BRCA2* families and noncarriers ($P=0.012$). All models did distinguish significantly the *BRCA1* families from the noncarriers ($P<0.0001$).

In order to visualise the predictive power of each model, ROC curves were generated for all models and the areas under the curves (C statistic) were determined. The Evans1 model outperformed all other models for the prediction of *BRCA1* mutation-positive families. The Evans2 model performed best for the prediction of *BRCA2* mutation-positive families. For all models we assessed the sensitivity for *BRCA1* mutation-positive families and *BRCA2* mutation-positive families for the advised cutoff levels (≥ 10 for all models). Thus, the Gilpin model scored best (sensitivity *BRCA1*: 100%; sensitivity *BRCA2*: 88%, two families missed). The Evans1 and Evans2 model scored disappointing for *BRCA2* families. Only 50% of all *BRCA2* families were selected. For *BRCA1* families, the Evans1 and Evans2 selection scored much better and only one family was missed. With the Frank model, four *BRCA1* mutation-positive families were missed (sensitivity of 88%) and four *BRCA2* mutation-positive families (sensitivity of 75%).

To improve the efficiency of selection for *BRCA* mutation testing, the sensitivity and specificity were calculated for various cutoff levels in all models (Table 2 and Supplementary data Table 1). As expected, the sensitivity decreased and the specificity increased when higher cutoff levels were used. However, no clear optimal combination of sensitivity and specificity could be reached. Scatter plots revealed that the models complement each other in several families (data not shown). Therefore, combinations of different cutoff levels of the two models were tested (Table 2 and Supplementary data Table 2).

Overall, the combination of two prediction scores had a higher sensitivity than each individual model although the specificity decreased. 'Frank ≥ 16 or Evans2 ≥ 12 ' showed the to be the best combination with respect to highest sensitivity and specificity (96 and 47%, respectively; Table 2). Only two mutation-positive families were missed. These two families were *BRCA2* mutation-positive families. In one of these families, a mother and daughter had developed breast cancer at age 56 and 26, respectively (Frank: 7.8%; Gilpin: 6; Evans1: 8; Evans2: 7). In the other family, two sisters had breast cancer at the ages 47 and 52 and one brother developed pancreatic cancer (Frank: 8.3%; Gilpin: 8; Evans2 (and 1): 5). Both families had very few female relatives. The combination of 'Frank ≥ 16 or Gilpin ≥ 16 ' had an almost equal sensitivity and specificity of 94 and 40%, respectively (Table 2).

To include such *BRCA* mutation-positive cancer families, five 'additional criteria' were introduced that are focussed on individual features of one affected person in a family at risk (Table 3). These criteria include all relatives from the index patient up till the third degree. Sensitivity, specificity and predictive values were calculated for all models and model combinations in combination with these 'additional criteria' (Table 2 and Supplementary data Table 3). To obtain an optimal sensitivity, we also varied the cutoff levels.

An optimal combination of sensitivity and specificity was obtained with the combination 'Frank ≥ 16 or Evans2 (or 1) ≥ 12 or one of the additional criteria'. However, this combination missed the same *BRCA2* mutation-positive family (the two sisters with breast cancer at the ages 47 and 52 and one brother with pancreatic cancer) as none of the 'additional criteria' were fulfilled. To obtain 100% sensitivity, the cutoff levels should be lowered such, that there is hardly any specificity gained relative to the initial selection based on expert opinion of clinical geneticists.

The specificity and positive predictive value were best for the combination 'Frank ≥ 16 or Evans1 (or 2) ≥ 12 or one of the additional criteria'. With this selection combination, 22% less families would have been tested for *BRCA* mutations than without these criteria. With the selection combination 'Frank ≥ 16 or Gilpin ≥ 16 or one of the additional criteria', this profit would have been 18%.

Validation

The selection combinations, 'Frank ≥ 16 or Gilpin ≥ 16 or one of the additional criteria' and 'Frank ≥ 16 or Evans1 (or 2) ≥ 12 or one of the additional criteria', were validated in a cohort of 197 breast/ovarian cancer families tested in 2002. With the combination 'Frank ≥ 16 or Gilpin ≥ 16 or one of the additional criteria' only one *BRCA2* family was missed. The same *BRCA2* family was also missed with the combination 'Frank ≥ 16 or Evans1 ≥ 12 or one of the additional criteria'. The combination 'Frank ≥ 16 or Evans2 ≥ 12 or one of the additional criteria' missed besides this *BRCA2* family also one *BRCA1* family. The specificity for these combinations varied between 18 and 21% and is less than that for the test group of 263 individuals. This difference may be due to a difference in selection stringency of both groups. The families that have been tested for *BRCA* mutations in 2002 scored higher median selection scores for all models than the families that have been tested between 1999 and 2001. The more stringent selection in 2002 thus explains the lower specificity in these analyses. Despite of that, about 15–17% of all tested families would not have been tested with these new selection combinations.

In the *BRCA2*-positive family that was missed with both the selection combinations 'Frank ≥ 16 or Gilpin ≥ 16 or one of the additional criteria' and 'Frank ≥ 16 or Evans1 ≥ 12 or one of the additional criteria', the index case had developed breast cancer at age 68. The mother and grandmother were both diagnosed with breast cancer at ages 37 and 40, respectively, but had died and could not be tested (Frank: 12%; Gilpin: 15; Evans1




Figure 1 Boxplot graphs from the Gilpin, Frank, Evans1 and Evans2 scores for the different families and their *BRCA* mutation status (*BRCA1* or *BRCA2* mutation negative; *BRCA1* mutation-positive; *BRCA2* mutation-positive). The line in the box indicates the median value of the data. The box itself contains the middle 50% of the data. The ends of the vertical lines indicate the minimum and maximum data values. The points outside the ends are outliers.

(and 2): 8). If the mother would have been chosen as the index, the Frank and Gilpin scores would have been higher than 16 and thus this family would have been included in the selection for *BRCA* testing.

A second validation was performed for the combination 'Frank ≥ 16 or Gilpin ≥ 16 or one of the additional criteria' in 101 *BRCA*-positive families genetically tested at the University Medical Centre Groningen (70 families with a *BRCA1* mutation and 31 families with a *BRCA2* mutation). Only one *BRCA2*-positive family was missed. In this family the index had developed breast cancer at age 61. Two sisters had also developed breast cancer but the ages were not known and these variables could therefore not be added in the scores. In this family, the lack of information is the cause of not meeting the selection criteria. This family would also have been missed with 'Frank ≥ 16 or Evans2 (or 1) ≥ 12 or one of the additional criteria'.

DISCUSSION

Efficacy of *BRCA1* and *BRCA2* mutation testing can be improved by selection of families using both a combination of existing probability models as well as higher cutoff levels than advised in the previous publications. With a combination of easy to apply probability models: 'Frank ≥ 16 or Evans ≥ 12 or one of the additional criteria' a sensitivity of 98% was obtained with a substantial reduction in the number of selected families for *BRCA* testing as compared to the isolated use of one of these probability models at cutoff level 10.

In our daily practice, the number of *BRCA* mutation analysis is rapidly growing. However, the percentage of families with a detected *BRCA* mutation is decreasing. This urged us to improve the efficacy of the selection for mutation testing under the precondition that no mutation carrying family is allowed to be

Table 2 Sensitivity, specificity, positive and negative predictive values for different existing probability models separately and in combination with each other and in combination with the 'additional criteria' at different cut off levels in 263 families

Models and cut off levels	Sensitivity	Specificity	Positive predictive value	Negative predictive value
Frank ≥ 16	(41/49) 84%	(110/214) 51%	(41/145) 28%	(110/118) 93%
Gilpin ≥ 16	(39/49) 80%	(135/214) 63%	(39/118) 33%	(135/145) 93%
Evans1 ≥ 10	(40/49) 82%	(119/214) 56%	(40/135) 30%	(119/128) 93%
Evans1 ≥ 12	(37/49) 76%	(154/214) 72%	(37/97) 38%	(154/166) 93%
Evans2 ≥ 10	(40/49) 82%	(116/214) 54%	(40/138) 29%	(116/125) 93%
Evans2 ≥ 12	(36/49) 73%	(160/214) 75%	(36/90) 40%	(160/173) 92%
Frank ≥ 16 or Gilpin ≥ 16	(46/49) 94%	(85/214) 40%	(46/175) 26%	(85/88) 97%
Frank ≥ 16 or Evans1 ≥ 10	(47/49) 96%	(80/214) 37%	(47/181) 26%	(80/82) 98%
Frank ≥ 16 or Evans1 ≥ 12	(47/49) 96%	(96/214) 45%	(47/165) 28%	(96/98) 98%
Frank ≥ 16 or Evans2 ≥ 10	(47/49) 96%	(84/214) 39%	(47/177) 27%	(84/86) 98%
Frank ≥ 16 or Evans2 ≥ 12	(47/49) 96%	(100/214) 47%	(47/161) 29%	(100/102) 98%
Evans1 ≥ 10 or Gilpin ≥ 16	(42/49) 86%	(104/214) 49%	(42/152) 28%	(104/111) 94%
Evans1 ≥ 12 or Gilpin ≥ 16	(41/49) 84%	(127/214) 59%	(41/128) 32%	(127/135) 94%
Evans2 ≥ 10 or Gilpin ≥ 16	(40/49) 82%	(113/214) 53%	(40/141) 28%	(113/122) 93%
Evans2 ≥ 12 or Gilpin ≥ 16	(40/49) 82%	(129/214) 60%	(40/125) 32%	(129/138) 93%
Frank ≥ 16 or additional criteria	(47/49) 96%	(64/214) 30%	(47/197) 24%	(64/66) 97%
Gilpin ≥ 16 or additional criteria	(44/49) 90%	(77/214) 36%	(44/181) 24%	(77/82) 94%
Evans1 ≥ 10 or additional criteria	(43/49) 88%	(75/214) 35%	(43/182) 24%	(75/81) 93%
Evans1 ≥ 12 or additional criteria	(42/49) 86%	(92/214) 43%	(42/164) 26%	(92/99) 93%
Evans2 ≥ 10 or additional criteria	(42/49) 86%	(77/214) 36%	(42/179) 23%	(77/84) 92%
Evans2 ≥ 12 or additional criteria	(41/49) 84%	(92/214) 43%	(41/163) 25%	(92/100) 92%
Frank ≥ 16 or Gilpin ≥ 16 or additional criteria	(48/49) 98%	(48/214) 22%	(48/214) 22%	(48/49) 98%
Frank ≥ 16 or Evans1 ≥ 10 or additional criteria	(48/49) 98%	(49/214) 23%	(48/213) 23%	(49/50) 98%
Frank ≥ 16 or Evans1 ≥ 12 or additional criteria	(48/49) 98%	(57/214) 27%	(48/205) 23%	(57/58) 98%
Frank ≥ 16 or Evans2 ≥ 10 or additional criteria	(48/49) 98%	(48/214) 22%	(48/214) 22%	(48/49) 98%
Frank ≥ 16 or Evans2 ≥ 12 or additional criteria	(48/49) 98%	(57/214) 27%	(48/205) 23%	(57/58) 98%

The best combinations are marked by shading.

Table 3 Additional selection criteria specific for small BRCA mutation positive families

1. Both breast and ovarian cancer (one or both diagnosed before age < 60 year)
2. Male with breast cancer (at any age)
3. Bilateral breast cancer (diagnosed before age 45 years)
4. Ovarian cancer diagnosed before age 40 years
5. Breast cancer diagnosed before age 35 years

missed. In our clinical genetic setting, five existing probability models for the selection of BRCA mutation-positive families were analysed: Claus, Frank, Gilpin, Evans1 and Evans2. The latter four showed a good correlation with the mutation status and were studied in more detail. Most risk assessment and prior probability models are based on two or more affected family members and thus form a general limitation for the selection of families that lack family history information or families with only a few women. Addition of so-called 'additional criteria' to these models increased the sensitivity to almost 100%. These 'additional criteria' are applicable for one affected individual. We applied these 'additional criteria' for all affected members in a family up to the third degree of the index person. In case no family member fulfils one of the 'additional criteria', the selection is dependent on the Frank, Gilpin or Evans score.

The prevalence of BRCA1 and BRCA2 mutations among all women diagnosed with an invasive breast cancer or ductal carcinoma *in situ* is similar, and varies between 0.4–2.6% and 1.4–2.4%, respectively (Peto *et al*, 1999; Sanjose *et al*, 2003; Claus *et al*, 2005). However, both in our settings as well as in the literature, the families known to carry a BRCA1 mutation outnumber those with a BRCA2 mutation by far (Newman *et al*, 1998; Syrjakoski *et al*, 2000; Claus *et al*, 2005). This may mean

that either BRCA2 mutations are less common or that a considerable number of families actually carrying a BRCA2 mutation are missed, most likely because they are not recognised by the current probability models. Consequently, a specific BRCA2 prediction model is needed. BRCA2 families differ less from BRCA-negative mutation families than BRCA1 families do and may therefore need stricter or different selection criteria. Additionally, an explanation may be found in the fact that mutations in either of the two genes are related to different life time risks for nonbreast cancers such as ovarian cancer and prostate cancer (Antoniou *et al*, 2003; Van Asperen *et al*, 2005). Evans *et al* (2004) developed the so-called Evans2 model for the selection of BRCA2 mutation-positive families. In our study, this model was analysed for different combinations and cutoff levels. Although 'Gilpin ≥ 16 ' scored most BRCA2 mutation-positive families compared to the other models, the Evans2 model showed the best accuracy for this type of families (area under the ROC curve). However, in our study group, 50% of the BRCA2 families were missed in case the previously published cutoff level of 10 was used.

The sensitivity for the selection of BRCA2 mutation-positive families of the Evans2 model was strikingly lower in our study as compared to the study by Evans *et al*. This difference may be explained by difference in selection of the study population or by a difference in carrier frequency between the British and the Dutch population.

One family from the validation group with a BRCA2 mutation was missed by the Frank model, because the index patient was older than 50 years. The same family was also missed by the Gilpin model as the family relation with affected relatives was too distant (mother and grandmother from the affected index developed breast cancer). When in this case the mother was chosen to be index, the family would score ≥ 16 for both the Gilpin and Frank

model and thus would fulfil our selection criteria. This underlines that application of the selection models for BRCA mutation testing preferably should start in a family member with either breast cancer at the youngest age or with bilateral breast cancer or with ovarian cancer. BRCA mutations can be missed when the person with the highest probability to carry a mutation is not used as index in applying the selection model.

During recent years many studies describing new risk assessment models, prior probability models or comparisons of the performance of some existing models have been published (De la Hoya *et al*, 2003; Domchek *et al*, 2003; Marroni *et al*, 2004). A well-known model is BRCAPRO. This program was validated retrospectively on families with and without a BRCA1 or BRCA2 mutation (Parmigiani *et al*, 1998; Berry *et al*, 2002). To use this model a computer is needed. We did not include it in this study

REFERENCES

- Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi O-P, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 72: 1117–1130
- van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HFA, Ausems MGEM, Menko FH, Gomez Garcia EB, Klijn JGM, Hogervorst FBL, van Houtwelingen JC, Van't Veer LJ, Rookus MA, van Leeuwen FE, on behalf of the Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. *J Med Genet* 42: 711–719
- Bermejo L, Hemminki K (2004) Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 and BRCA2 mutation testing. *Ann Oncol* 15: 1834–1841
- Berry DA, Iversen Jr ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. *J Clin Oncol* 20: 2701–2712
- Claus EB, Petruzella S, Matloff E, Carter D (2005) Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma *in situ*. *JAMA* 293: 964–969
- Claus EB, Schildkraut J, Iversen Jr ES, Berry D, Parmigiani G (1998) Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. *J Natl Cancer Inst* 90: 1824–1829
- De la Hoya M, Diez O, Perez-Segura P, Godino J, Fernandez JM, Sanz J, Alonso C, Baiget M, Diaz-Rubio E, Caldes T (2003) Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. *J Med Genet* 40: 503–510
- Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL (2003) Application of breast cancer risk prediction models in clinical practice. *J Clin Oncol* 21: 593–601
- Evans DGR, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. *J Med Genet* 41: 474–480
- Evans DGR, Lalloo F, Wallace A, Rahman N (2005) Update on the Manchester scoring system for BRCA1 and BRCA2 testing. *J Med Genet* 42: e39
- Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpfer KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. *J Clin Oncol* 20: 1480–1490
- aimed to determine optimal prediction using a simple, quick and easy to apply probability model. In the present study we succeeded to optimise existing easy applicable models by combining them and adjusting the cutoff levels to a more specific and sensitive selection.

ACKNOWLEDGEMENTS

The authors thank S Vermeer for supplying the pedigrees used in this manuscript, genetic counsellors for gathering the family history, technicians for performing mutation analyses.

Supplementary Information accompanies the paper on British Journal of Cancer website (<http://www.nature.com/bjc>)

- Gilpin CA, Carson N, Hunter AG (2000) A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics centre. *Clin Genet* 58: 299–308
- Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonck R, Menko FH, Kluij I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G (2003) Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. *Cancer Res* 63: 1449–1453
- Hout van der AH, Mulder IM, Wu Y, van der Vlies P, Huisman M, Oosterwijk JC, Buys CHCM, Hofstra RMW (1999) A DGGE system for comprehensive mutation screening of the complete coding regions of BRCA1 and BRCA2 outside exons 11. *Am J Hum Genet* 65: A410
- Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, Bosgoed EA, Van der Looij E, Rookus MA, Devilee P, Vos EM, Wigbout G, Struycken PM, Menko FH, Rutgers EJ, Hoefsloot EH, Mariman EC, Brunner HG, Van't Veer LJ (1999) Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. *Br J Cancer* 79: 1475–1478
- Marroni F, Aretini P, D'Andrea E, Caligo MA, Cortesi L, Viel A, Ricevuto E, Montagna M, Cipollini G, Ferrari S, Santarosa M, Bisegna R, Bailey-Wilson JE, Bevilacqua G, Parmigiani G, Presciuttini S (2004) Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. *J Med Genet* 41: 278–285
- Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC (1998) Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. *JAMA* 279: 915–921
- Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. *Am J Hum Genet* 62: 145–158
- Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. *J Natl Cancer Inst* 91: 943–949
- Sanjose S, Leone M, Berez V, Izquierdo A, Font R, Brunet JM, Louat T, Vilardell L, Borrás J, Viladiu P, Bosch FX, Lenoir GM, Sinilnikova OM (2003) Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. *Int J Cancer* 106: 588–593
- Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. *Nucleic Acids Res* 30: e57
- Syrjäkoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. *J Natl Cancer Inst* 92: 1529–1531